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Abstract: Post-transplant lymphoproliferative disorder (PTLD) is one of the most common malignancies
after solid organ or allogeneic stem cell transplantation. Most PTLD cases are B cell neoplasias carrying
Epstein-Barr virus (EBV). A therapeutic approach is reduction of immunosuppression to allow T cells
to develop and combat EBV. If this is not effective, approaches include immunotherapies such as mon-
oclonal antibodies targeting CD20 and adoptive T cells. Immune checkpoint inhibition (ICI) to treat
EBV+ PTLD was not established clinically due to the risks of organ rejection and graft-versus-host dis-
ease. Previously, blockade of the programmed death receptor (PD)-1 by a monoclonal antibody (mAb)
during ex vivo infection of mononuclear cells with the EBV/M81+ strain showed lower xenografted lym-
phoma development in mice. Subsequently, fully humanized mice infected with the EBV/B95-8 strain
and treated in vivo with a PD-1 blocking mAb showed aggravation of PTLD and lymphoma develop-
ment. Here, we evaluated vis-a-vis in fully humanized mice after EBV/B95-8 or EBV/M81 infections
the effects of a clinically used PD-1 blocker. Fifteen to 17 weeks after human CD34+ stem cell trans-
plantation, Nod.Rag.Gamma mice were infected with two types of EBV laboratory strains expressing
firefly luciferase. Dynamic optical imaging analyses showed systemic EBV infections and this triggered
vigorous human CD8+ T cell expansion. Pembrolizumab administered from 2 to 5 weeks post-infections
significantly aggravated EBV systemic spread and, for the M81 model, significantly increased the mor-
tality of mice. ICI promoted Ki67+CD30+CD20+EBER+PD-L1+ PTLD with central nervous system
(CNS) involvement, mirroring EBV+ CNS PTLD in humans. PD-1 blockade was associated with lower
frequencies of circulating T cells in blood and with a profound collapse of CD4+ T cells in lymphatic
tissues. Mice treated with pembrolizumab showed an escalation of exhausted T cells expressing TIM-3,
and LAG-3 in tissues, higher levels of several human cytokines in plasma and high densities of FoxP3+
regulatory CD4+ and CD8+ T cells in the tumor microenvironment. We conclude that PD-1 blockade
during acute EBV infections driving strong CD8+ T cell priming decompensates T cell development
towards immunosuppression. Given the variety of preclinical models available, our models conferred a
cautionary note indicating that PD-1 blockade aggravated the progression of EBV+ PTLD.
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Post-transplant lymphoproliferative disorder (PTLD) is one of the most common
malignancies after solid organ or allogeneic stem cell transplantation. Most PTLD cases
are B cell neoplasias carrying Epstein-Barr virus (EBV). A therapeutic approach is
reduction of immunosuppression to allow T cells to develop and combat EBV. If this is
not effective, approaches include immunotherapies such as monoclonal antibodies
targeting CD20 and adoptive T cells. Immune checkpoint inhibition (ICI) to treat EBV+
PTLD was not established clinically due to the risks of organ rejection and graft-versus-
host disease. Previously, blockade of the programmed death receptor (PD)-1 by a
monoclonal antibody (mAb) during ex vivo infection of mononuclear cells with the EBV/
M81+ strain showed lower xenografted lymphoma development in mice. Subsequently,
fully humanized mice infected with the EBV/B95-8 strain and treated in vivo with a PD-1
blocking mAb showed aggravation of PTLD and lymphoma development. Here, we
evaluated vis-a-vis in fully humanized mice after EBV/B95-8 or EBV/M81 infections the
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effects of a clinically used PD-1 blocker. Fifteen to 17 weeks after human CD34+ stem cell
transplantation, Nod.Rag.Gamma mice were infected with two types of EBV laboratory
strains expressing firefly luciferase. Dynamic optical imaging analyses showed systemic
EBV infections and this triggered vigorous human CD8+ T cell expansion. Pembrolizumab
administered from 2 to 5 weeks post-infections significantly aggravated EBV systemic
spread and, for the M81 model, significantly increased the mortality of mice. ICI promoted
Ki67+CD30+CD20+EBER+PD-L1+ PTLD with central nervous system (CNS) involvement,
mirroring EBV+ CNS PTLD in humans. PD-1 blockade was associated with lower
frequencies of circulating T cells in blood and with a profound collapse of CD4+ T cells
in lymphatic tissues. Mice treated with pembrolizumab showed an escalation of
exhausted T cells expressing TIM-3, and LAG-3 in tissues, higher levels of several
human cytokines in plasma and high densities of FoxP3+ regulatory CD4+ and CD8+ T
cells in the tumor microenvironment. We conclude that PD-1 blockade during acute EBV
infections driving strong CD8+ T cell priming decompensates T cell development towards
immunosuppression. Given the variety of preclinical models available, our models
conferred a cautionary note indicating that PD-1 blockade aggravated the progression
of EBV+ PTLD.
Keywords: humanized mice, immuno-oncology, Epstein-Barr Virus (EBV), immune checkpoint inhibition (ICI), post-
transplant lymphoproliferative disease (PTLD), lymphoma, PD-1, pembrolizumab
INTRODUCTION
EBV is an oncogenic g-herpesvirus associated with around 2% of
all human cancers such as hematologic and epithelial malignancies
(1). After the primary infection, EBV lytic reactivations are
immunologically controlled, but the virus is not cleared. The
life-long EBV maintenance in the host does not always lead to
cellular transformations, but dysfunctional immunity can
predispose opportunistic flares of EBV reactivations and
eventually lead to EBV+ infectious mononucleosis (IM),
lymphoproliferative diseases (LPD), or malignancies (2). Thus,
novel immunotherapeutic options are being developed and tested
for treatment of EBV infections and/or EBV-associated
malignancies. For example, immune checkpoint inhibition (ICI)
with monoclonal antibodies (mAbs) became a major
breakthrough immunotherapy for cancer treatment over the
past decade and showed to be effective against several types of
tumors. Currently, several mAbs blocking the programmed death
receptor protein (PD)-1 or its ligand PD-L1 have been approved
or are in clinical development against several types of cancer (3, 4).
ICI has demonstrated impressive high response rates as salvage
therapy in relapsed/refractory (R/R) classical Hodgkin lymphoma
(cHL) (5), the most common cancer among young people.
Incidentally, EBV contributes to the chronic inflammatory
microenvironment of a subset of cHL with high expression of
PD-L1. Indeed, the interaction of PD-L1 with PD-1 on
inflammatory T cells constitutes one of the major immune
escape mechanisms in cHL, associated with development of
dysfunctional and tolerogenic T cell responses (5). The
preclinical observation of PD-L1 overexpression in cHL led to
the evaluation of ICI administration in several clinical trials and
the subsequent clinical approval of nivolumab, a mAb blocking
PD-1, for cHL therapy (6). In 2017, The U.S. Food and Drug
Administration also granted approval to pembrolizumab
(KEYTRUDA®), another PD-1 blocking mAb, for the treatment
of adult and pediatric patients with refractory cHL.
Another important clinical scenario is the EBV-associated
post-transplant lymphoproliferative disorder (PTLD), a severe
complication occurring in immunocompromised hosts after
allogeneic hematopoietic stem cell transplantation (allo-HCT)
or solid organ transplantation (SOT). The diagnostic of PTLD
categories proposed by World Health Organization (WHO) are
early lesions, polymorphic PTLD, monomorphic PTLD, and also
cHL (7). Diffuse large B-cell lymphoma (DLBCL) accounts for
the majority of the cases of PTLD. Development of aggressive
EBV+ DLBCL has been associated with both latent and lytic viral
cycles (8). The EBV+ DLBCL subtype is amonomorphic B cell
lymphoma positive for EBV-encoded small RNAs (EBER) and
characteristically expressing pan-B-cell markers (CD19, CD20,
and occasionally CD30) with an EBV latency pattern type III in
which all latency genes are expressed [for an expert review see
(9)]. A small number of lytic infected cells can be found in
tumors and show expression of lytic transcripts (such as BZLF1
and gp350) (8). A biomarker for these malignancies is the
frequently detectable high expression of PD-L1 (CD274 and
also known as B7-H1) in EBV+ PTLD, cHL, and DLBCL (10–12).
PD-L1 induction in EBV+ malignancies occurs via AP-1 and
JAK/STAT pathways (10) and also through the cooperation of
EBV-LMP-1 and IFN-g signaling (13). For EBV+ DLBCL, the
PD-L1 positive tumors express high levels of indoleamine
2,3-dioxygenase (IDO), indicating a tolerogenic tumor
microenvironment (TME) (11). Furthermore, EBV+ DLBCL
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presents with a distinct tolerogenic TME than EBV− DLBCL,
characterized by elevated expression of immune checkpoints
[PD‐L1, PD‐L2, lymphocyte activation gene 3 (LAG-3) and T
cell immunoglobulin and mucin domain-containing protein 3
(TIM-3)] and high levels of immunosuppressive M2‐type
macrophages (12). Thirty to 40% of DLBCL patients show
primary resistance or early relapse after standard therapy and
there is no standard treatment approach specifically for
aggressive EBV+ DLBCL (9).
The standard of care for PTLD/DLBCL is first a reduction in
immunosuppression, that needs to be adjusted to the clinical
situation, e.g. potential risks for transplant rejection or graft-
versus-host disease (GvHD) (2). Additionally, treatment with
rituximab, a mAb that targets the CD20+ malignant cells,
produces response rates of about 65% (14). Clinical trials in
specialized centers demonstrated that adoptive administration
of third party or donor-derived or T cells specific for EBV could
effectively restore virus-specific immunity and confer
protection in 60 to 90% of transplant recipients with a PTLD
(15). In addition to these measures, use of ICI could be a
promising approach to treat EBV+ PTLD (10). Nonetheless, since
the immunity of patients after transplantations is not in the normal
homeostatic steady state, the clinical use of ICI against PTLD
demands careful preclinical testing, particularly due to the
associated risks of graft rejection and graft-versus host
disease (GvHD).
EBV strictly infects human cells and therefore special in vivo
models are required for preclinical testing of therapies targeting
an EBV+ malignancy or immunopathology. During the last
decade, mice reconstituted with the human immune system
(“HIS mice”) became the state-of-the art in vivo models to test
human-specific therapies against several human infections,
malignancies, immunological and metabolic diseases (16–18).
Infection of HIS mice with different EBV strains recapitulated
several hallmarks of PTLD and lymphoma development and,
concurrently, allowed studies of the human T cell inflammatory
immune responses (19–22). The EBV/B95-8 strain was originally
isolated from a patient with infectious mononucleosis and was
later modified into the engineered B95-8/GFP strain, produced
in the laboratory with the bac-mid technology. B95-8/GFP
promotes a high B cell transformation rate and B-cell
lymphoma growth (23). We have previously shown that, a few
weeks after infection of HIS mice with B95-8/GFP, a dramatic
expansion of CD8+ T cells expressing the inhibitory receptors
PD-1, LAG-3, and TIM-3 followed (24, 25). Another strain,
EBV/M81, was originally isolated from a patient with
nasopharyngeal carcinoma (26). The M81/GFP engineered
laboratory derivative induces potent lytic replication in B cells
both in vitro and in humanized mice also leading to development
of tumors (23).
Previously, therapeutic effects of PD-1 blockade in a xenograft
mouse model of M81/GFP+ lymphoma were reported (27)
(Table 1). Mononuclear cells obtained from cord blood (CB)
were infected in vitro with the M81/GFP strain and then injected
i.p. into Nod.Scid.Gamma (NSG) mice. Tumors resembling
diffuse large B cells lymphoma (DLBCL) developed 3–5 weeks
after in spleen. Pre-treatment of the cells with mAbs in vitro, i.e.,
prior to administration into the mice, significantly lowered the
development of EBV+ tumors, particularly when anti-PD-1 and
anti-CTLA-4 mAbs were combined (27). More recently, the
Münz laboratory showed that fully humanized mice infected
with B95-8/GFP and afterwards treated with a PD-1 blocking
mAb showed significant increase in EBV viral load and tumor
development (25) (Table 1). The interpretation of these results
was that the disruption of the PD-1/PD-L1 axis during the T cell
priming phase abrogated functionality of CD8+ CTLs, required
to keep EBV infection and tumor development under
control (25).
In view of these opposite results, we sought to clarify these
discrepancies in fully humanized mice comparing head-to-
head the two EBV strains used for infection models (Table 1).
NOD.Rag.Gamma (NRG) HIS mice were infected either with
EBV/B95-8/fLuc or EBV/M81/fLuc and dynamic non-invasive
monitoring of viral spread and post-mortem immunological
and histological analyses were performed as previously
reported (24, 28). We show a dose-dependent effect of
pembrolizumab augmenting the EBV systemic dissemination,
lymphomagenesis, and increasing mortality. Remarkably,
pembrolizumab treatment promoted EBV spread into the
central nervous system (CNS) recapitulating CNS-PTLD.
These severe effects of PD-1 blockade were associated with a
decompensation of the systemic and intra-tumoral pattern of
CD4+ T cells and accumulation of cytokines and FoxP3+ T
cells. Thus, although PD-1 blockade may be a favorable
therapeutic option against some EBV+ tumors, these models
show that it can aggravate the EBV infections in the context of
PTLD, promoting hyper-progressive disease (HPD), morbidity,
and mortality.
MATERIAL AND METHODS
Generation of Humanized NRG Mice
Collection of CB was performed at the Department of
Gynecology and Obstetrics (Hannover Medical School) and
obtained according to study protocols approved by the
Ethics Committee of the Hannover Medical School and after
informed consent obtained from the mothers. Human CD34+
hematopoietic cells were isolated from CB after two rounds of
positive selection using immune magnetic beads (Direct CD34
Progenitor Cell Isolation Kit, human, MACS Miltenyi Biotec,
Bergisch Gladbach, Germany) as described (24, 28–30). All
experiments involving mice were approved by the Lower
Saxony Office for Consumer Protection and Food Safety–
LAVES (permit number: 16/2222) and performed in
accordance with the German animal welfare act and the EU-
directive 2010/63. Breeding pairs of NOD:Cg − Rag1tm1MomIL −
2Rg
tm1Wjl
c (NRG) mice were obtained from the Jackson
Laboratory (JAX; Bar Harbor, USA) and bred under pathogen-
free conditions. Prior to HCT, 5–6 weeks-old mice were
sublethally irradiated (450 cGy) using a [137Cs] column
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irradiator (Gammacell 3000 Elan; Best Theratronics, Ottawa,
Canada). Four hours after irradiation, 2.0 × 105 CD34+ cells were
injected through the tail vein. Body weight and occurrence of
GvHD were monitored weekly after HCT. For the sake of
reproducibility, we used preferentially female NRG mice
because they show more consistent and stable human immune
reconstitution and immune responses >15 weeks after HCT (29).
Further, CD34+ HSC units were pretested in a couple of
transplanted NRG mice and only those resulting in 20% or
higher frequencies of human CD45+ cells in mouse blood at
10–15 weeks post-HCT were used for experiments with EBV
infections. These parameters were extensively optimized for
preclinical testing of vaccines and chimeric antigen receptor
(CAR) T cell therapies (28, 30–33).
EBV Infections and Treatment of
Humanized Mice With Pembrolizumab
Stable human hematopoietic engraftment was confirmed in
peripheral blood at 15–17 weeks after HCT, and at this point
mice were infected with the B95-8/fLuc (24) or with the M81/
fLuc strain (28, 34). The engineered B95-8/fLuc strain expresses
the reporter gene firefly luciferase downstream of the viral
Epstein-Barr nuclear antigen 2 (EBNA2) (24), while the EBV/
M81/fLuc strain expresses fLuc under the control of an inserted
CMV immediately early (IE)1 promoter sequence (34). EBV
titers were defined as green Raji units (GRU) after infection of
Raji cells with serial dilutions of the virus stocks. The percentage
of GFP+ cells was analyzed by flow cytometry 3 days later and the
viral titers were calculated by the following formula: “total
TABLE 1 | Summary of experimental approaches and conclusions from three different animal studies evaluating in vivo the effects of PD-1 blockade on EBV infection
and tumor development.













cells. Dose: 12–25× 10e6 cells/
mouse
HLA-A2+ CD34+ isolated HSCs
Dose: 1–3 × 10e5 HSCs/mouse
CD34+ isolated HSC




weeks old at cell transfer
NSG w.t. or expressing HLA-A2/Jackson
Laboratory/HCT in newborns up to 5 days of age





Intraperitoneal cell transfer after in
vitro infection/Euthanasia at
endpoint 4 weeks after cell
transfer, or earlier if clinically ill
Fully humanized model/Sublethally irradiated (1 Gy)/
intrahepatic HCT/EBV infection 12 weeks after HCT/
Bleedings 2, 3, 4, 5 wpi/Euthanasia at endpoint 5
wpi, or earlier if ill
Fully humanized model/Sublethally irradiated (4.5 Gy)/IV HCT/
EBV infection 15–17 weeks after HCT/Bleedings 0, 2, 3–4, 5–
6, 8 wpi/Optical Imaging 2, 3–4, 5–6 wpi/Euthanasia at
endpoint 8 wpi, or earlier if ill
Human
Immunity
Spleen and tumors at endpoints.
FACS: HLA-A/B/C, CD45, CD3,
CD19, CD20, PD-L1, PD-L2, PD-
1, CTLA-4
Blood FACS: CD45, CD19, CD3, CD4, CD8
Endpoint FACS CD3, CD8, CD19, CD27, CD28,
CD45, CD45RA, CD62L, CTLA4, HLA-DR, Ki67
LAG-3, PD-1, PD-L1, Tim-3 and other analyses of
human cytokines in plasma
Blood analyses FACS: CD45, CD19, CD3, CD4, CD8
Endpoint FACS CD3, CD8, CD19, CD45, PD-1, LAG-3, TIM-3
FoxP3
Analyses of human cytokines in plasma
Human
Infections
EBV M81/GFP produced in
HEK293/tittered on Raji cells/CB
cells infected in vitro with 2,000 to
5,000 infectious units
for 1.5 h
B95-8/GFP produced in HEK293/Tittered on Raji
cells/EBV infection IP with 10e5 infectious units/Viral
load: DNA isolated from spleen and whole blood and
RT-qPCR
B95-8/fLuc/GFP and EBV M81/fLuc/GFP produced in
HEK293/tittered on Raji cells/B95-8 10e5 and M81 10e6
infectious units IV/Followed for up 8 wpi/Viral load: DNA
isolated from spleen and bone marrow and RT-qPCR
Human
Oncology
Lymphoma development 4 weeks
after cell transfer/spleen and
organs H&E staining/IHC staining
CD20, CD8, CD4/EBV antigens:
EBER, EBNA2, LMP1, BZLF1,
BMRF
PTLD and lymphoma terminal analyses 5 wpi/Spleen
IHC EBNA1, EBNA2, EBER
PTLD and lymphoma terminal analyses 8 wpi/Spleen, liver,






No ICI in vivo/Anti-CTLA-4 mAb
(Ipilimumab)/anti-PD-1 mAb (anti-
hCD279, clone J116 BioXcell)/3×
weekly (100 mg i.p.), starting 5–10
days after cell transfer until 4
weeks after cell transfer/Control
huIgG
ICI applied in vitro reduced
lymphomas as single therapies
(P=0.06) or combination (P=0.03)/
combination, lowered # latently,
and lyrically infected B cells,
increased EBV-specific T cell
responses
ICI considered useful for
treating EBV-induced diseases
ICI starting 3 wpi applied a total of 7× until 5 wpi/
Anti-PD-1 mAb (clone EH12.2H7 Biolegend) 100–
150 mg per administration/7× administrations/
Control: PBS or 150 mg of isotype control antibody
ICI applied during in vivo T cell priming resulted in
elevated viral load (blood P < 0.05, spleen P <
0.001), elevated tumor burden (P < 0.05./CD3 T cell
numbers in blood not changed/Lower frequencies of
PD-1+ CD8 T cells (P < 0.0001)/Elevated levels of
cytokines (IFN-g, TNF-a, IL-10, IL-8 P < 0.05 to P <
0.001)
Function of PD-1 axis necessary for control of
EBV infection and tumorigenesis
ICI low dose: 1st administration 3.33 mg/kg at 2 wpi; 1.7 mg/
kg every other week applied 6×)/ICI high dose (1st 10 mg/kg at
2 wpi; 5 mg/kg every other week applied 6×)
ICI applied during in vivo T cell priming resulted in elevated viral
spread (BLI) load (spleen and bone marrow), elevated tumor
burden (also in CNS) and higher mortality/CD4 and CD8 T cell
numbers in blood reduced, lower frequencies of PD-1+ CD8
and CD4 T cells/Increased frequencies of TIM-3+, LAG-3+ and
Tregs/elevated levels of cytokines (IFN-a, IL-10, IL-33, IL-12)
PD-1 blockade worsens PTLD and lymphomagenesis
with the emergence of immune dysfunctional T cells
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number of Raji cells infected” × “percentage of GFP+ cells”/
”volume of the virus stock used.” After pilot experiments to
evaluate the relationship between the viral dose and reproducible
bioluminescent signals detectable at 2 weeks post infection (wpi),
the viral doses diluted in 100 µl PBS were established: 105 GRU
for EBV/B95-8/fLuc and 106 GRU for EBV/M81/fLuc (Table 1).
Using these viral doses, we have reported that most of the
infected HIS mice survive for more than 8 wpi with some mice
showing progressive disease while others are able to control the
tumor development with stable disease (24, 28). Euthanasia was
performed at the endpoint 8 wpi for collection of biopsies or
earlier if symptoms of distress due to tumor development or
weight loss were detected. At 2 wpi, mice were randomized based
on their bioluminescence signal between PBS control,
pembrolizumab high dose (HD) and pembrolizumab low dose
(LD). Pembrolizumab (MSD; Kenilworth; USA) was diluted in
PBS for administration as a low dose (LD: First administration
3.33 mg/kg at 2 wpi; 1.7 mg/kg every other week applied six times)
or as a high dose (HD: First administration 10 mg/kg at 2 wpi; 5
mg/kg every other week applied six times). As treatment controls
PBS or human pooled immunoglobulin (KIOVIG, a clinically
used pooled polyclonal IgG product obtained from human
donors) were injected intraperitoneally every week after 2 wpi.
Flow Cytometry Analysis of Blood
and Lymphatic Tissues
Peripheral blood (BL) obtained at different time-points and
tissues obtained from humanized mice at the endpoint [lymph
node (LN), spleen (SPL), bone marrow (BM), thymus (Thy)]
were processed as previously described (24, 29, 30). For BL and
SPL, a hypotonic solution (0.83% ammonium chloride/20 mM
HEPES, pH 7.2, for 5 min at room temperature) was used to
remove erythrocytes. Flow cytometry acquisitions were
performed with fresh or cryopreserved/thawed cells after
immune staining (see antibodies used in Table S10). After
washing of unbound antibodies, cells were acquired with an
LSR II cytometer (BD bioscience) or Cytoflex cytometer
(Beckman Coulter). Data was analyzed with FlowJo (LLC, USA).
Dynamic Bioluminescence Imaging (BLI)
Analysis
Viral infection and spread in the mice were monitored by expression
of luciferase in tissues infected with EBV/B95-8/fLuc or with EBV/
M81/fLuc. Dynamic BLI analyses were performed with the IVIS
SpectrumCT apparatus (PerkinElmer, Waltham, MA, USA). Before
imaging, mice were anesthetized using isoflurane. Mice were imaged
5 min after luciferin administration [2.5 mg D-luciferin potassium
salt intraperitoneally (SYNCHEM, ELK Grove Village, IL, USA)
reconstituted in 100 µl PBS]. Data was analyzed using the Living
Image Software (PerkinElmer, Waltham, MA, USA).
Quantification of Epstein–Barr Virus
by Real-Time Quantitative PCR
DNA was isolated from tissues using the DNeasy Blood&Tissue
Kit (QIAGEN, Venlo, Netherlands) following the manufacturer´s
protocol. In order to detect EBV DNA, a quantitative PCR (qPCR)
was performed by amplifying a fragment of the BALF5 gene using
following primers: 5´-CTTTGGCGCGGATCCTC-3´ (forward)
and 5´-AGTCCTTCTTGGCTAGTCTGTTGAC-3´ (reverse).
Detection of the amplification was performed with the following
Taqman probe: 5´-Fam-CATCAAGAAGCTGCTGGCGGCC-
Tamra-3´. EBV copy number was normalized per µg of isolated
DNA. The Taqman PCR assays were run in duplicates on the
StepOnePlusTM Real-time system (Applied Biosystems, Life
Technologies, Darmstadt, Germany). Data was analyzed using
the StepOnePlusTM software (Applied Biosystems, Life
Technologies, Version 2.3).
Cytokine Analysis in Mouse Plasma
Cytokine concentrations in plasma samples were determined
using the LEDGENDplex™ Human Inflammation Panel 1
Multi-Analyte Flow Assay (BioLegend, San Diego, USA),
which allowed for the simultaneous detection of IFN-a, IFN-g,
IL-1b, IL-6, IL-8, IL-10, IL-12p70, IL-17A, IL-18, IL-23, IL-33,
MCP-1, and TNF-a. The assay was performed according to the
manufacturer’s instructions. Briefly, undiluted samples and
standards were incubated with antibody-coated premixed
beads overnight at 4°C followed by incubation with detection
antibody for 1 h at room temperature and streptavidin-PE for
30 min at room temperature. Samples were read on a BD
FACSCanto™ Flow Cytometer (BD Biosciences, Heidelberg,
Germany) and analyzed with the LEGENDplex v8.0 Software
(BioLegend, San Diego, USA).
Histopathology, Immunohistochemistry,
and Image Analysis
Three-µm-thick tissue sections were cut from formalin-fixed,
paraffin-embedded (FFPE) tissue blocks containing mouse SPL
and LI. Staining was performed according to standard protocols
for Giemsa. Immunohistochemistry analyses were performed
using the Benchmark Ultra automated instrument (Ventana/
Roche Tissue Diagnostics, Mannheim, Germany). Following
antibodies were used for tissue staining: Ki67 (clone RM9106-
S1; ThermoScientific), CD20 (clone M0755; Dako), CD30 (Ber-
H2; Dako), CD3 (clone M7254; Dako), programmed cell death
ligand 1 (PD-L1; clone 22C3; Dako), CD8 (clone C8/144B; Dako,
Copenhagen, Denmark), CD4 (clone SP35; Zytomed Systems,
Berlin, Germany), PD-1 (MRQ-22; Medac Diagnostika, Wedel,
Germany), FoxP3 (cat. number 560046; BD) (vendor information
available in Table S10). For antibody binding detection, the 3,3-
diaminobenzidine based UltraView reagent was used according to
the manufacturer’s recommendations. EBER-1 detection was
performed by an in situ hybridization method (EBER 1 DNP
Probe, Ventana/Roche Tissue Diagnostics) and the automated
Benchmark Ultra instrument. Whole Slide Scans were produced
using an Aperio AT2 scanner (Leica Biosystems), images were




Three-µm-thick FFPE tissue slides were deparaffinized and
antigen retrieval was performed according to “Opal Multiplex
IHC Assay Development Guide” instructions. Blocking was done
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using Protein Block Serum-free (Dako) solution before each
staining cycle. Staining panel was designed to include primary
antibodies against human CD4, CD8, FoxP3 (or CD30 for brain
tissue staining), CD20, and Ki67. Secondary HRP Labelled
Polymer mouse/rabbit (Dako EnVision+ System- HRP Labelled
Polymer) antibodies were applied after washing step and
maintained for 10 min at room temperature, followed by
10 min incubation with tyramide fluorophores (Opal 520, Opal
570, Opal 620, Opal 650 or Opal 690, Akoya) used for signal
amplification. DAPI (Akoya) was used for nuclear staining and
Fluoromount-G mounting medium (ThermoScientific) was
applied to cover slides before imaging. Whole slide tissue
scanning was done at 40× magnification using the “Vectra
Polaris” (Akoya) platform. Spectral libraries were generated
using single stained scans of tonsil tissue for each marker and
images deconvolution was done with the inForm Advanced
Image Analysis software (inForm v2.4.8; Akoya). Several
representative spleen and liver images were used to train pre-
designed machine learning algorithms within inForm software to
define tissue classes (tumor, parenchyma, and blank area), adjust
cell segmentation settings, and phenotype cells. All the settings
from the training images were applied for batch analysis of
scanned images.
Statistical Analyses
Log-rank (Mantel-Cox) test was used to compare survival curves.
Fisher’s exact test was applied to compare the number of
macroscopically visible tumors between treatment groups.
Unpaired Welch’s t test was used to calculate statistical
significance for kinetics of immune reconstitution, EBV and T cell
levels in tissues. Mann-Whitney t test was used for analyses of
cytokines concentrations. P < 0.05 was considered statistically
significant. Log-transformation of absolute numbers was done for
BLI, RT-qPCR, PD1/CD4, and PD1/CD8 MFI, and cell count
results, to compare the distribution of measurements within
different groups; we also tested the equality of one-dimensional
probability distributions using a two-sample Kolmogorov-Smirnov
(KS) test. The KS statistic (D), defined as the maximal vertical
distance between the empirical cumulative distributions between the
groups, and significance level (p-value) were calculated and used as
two criteria for finding biomarkers with significant difference
between experimental groups. The biomarkers with high KS
statistics and low p-value are reported. Statistical analyses were
performed using GraphPad Prism v7 software (GraphPad Software
Inc., La Jolla, CA, USA). KS test was performed using the statistical
computing software R (version 3.4.3).
Data Analyses
Quantitative imaging analyses of data tables exported from
inForm 2.4.8. (Akoya) were performed using “R” packages
“Phenoptr” and “PhenoptrReports” (Kent S Johnson (2019).
phenoptr: inForm Helper Functions. R package version 0.2.3.).
Analyses were performed using Rstudio (Rstudio v1.1.456). See
also: https://www.r-project.org/foundation/. The readout
protocols combined results for “Cell absolute counts,” “Cell
percentages,” “Cell densities,” and “Counts within” following
manufacturer’s instructions (Phenoptics™, Akoya).
RESULTS
PD-1 Blockade in Fully Humanized Mice
Promoted Epstein–Barr Virus Spread,
Tumor Development, and Mortality
Pembrolizumab administration (“Pembro”) or the control
treatment (“CTR”, PBS or KIOVIG) were initiated at 2 wpi, after
a baseline BLI measurement was performed in order to allocate
mice in comparable treatment arms (Figure 1A). The
pembrolizumab low and high dose were previously determined in
studies of humanized mice challenged with breast cancer and
treated with the drug (35). EBV-infected mice were monitored for
clinical signs of disease and euthanized based on humane endpoint
criteria. BLI analyses were performed serially until 8 wpi. All B95-8/
fLuc-infected mice treated with ICI survived until the end of the
experiments (Figure 1B). In contrast, several mice infected with
M81/fLuc and ICI-treated died prematurely and could not be
analyzed or were euthanized (3/6 mice in the LD and in 6/6 in
the HD cohort (survival of CTR vsHD, P < 0.01) (Figure 1C, Table
S1). Mice infected with B95-8/fLuc treated with pembrolizumab or
PBS showed comparable body weights (Figure 1D), while mice
infected with M81/fLuc treated with HD pembrolizumab showed
weight loss compared with the other arms (Figure 1E). For control
infected mice, tumors typically developed in the spleen, while most
ICI-treated mice showed multiple tumors located in different
organs, such as liver, lung, and kidney (Figures 1F, G). At the
baseline analyses before ICI treatment (2 wpi), EBV infection levels
assessed by BLI analyses were comparable, and over time showed
dynamic changes in intensities and bio-distribution. Remarkably,
the BLI signals in the ICI-treated animals increased dramatically
after 6–8 wpi indicating higher EBV dissemination (8 wpi: B95-8:
CTR vs Pembro, P < 0.0001; M81: CTR vs Pembro, P = 0.1387)
(Figures 1H, I, J, L, Table 2, Table S2). The EBV copy numbers in
SPL and BM were higher in ICI-treated mice infected with B95-8/
fLuc (Figure 1K, Table 2, Table S3, P = 0.199 and P = 0.111,
respectively) or with M81/fLuc than in controls (Figure 1M, Table
2, Table S3, P < 0.05). In summary, pembrolizumab administration
caused higher viral spread, viral load, tumor development for both
EBV infection models. The M81/fLuc lytic model showed the
highest severity leading to early mortality occurrences.
PD-1 Blockade Promotes Development of
Larger Epstein–Barr Virus+ PD-L1+ Tumor
Masses With Lower Densities of Tumor-
Infiltrating Lymphocytes
Next, we dissected the effects of pembrolizumab at the tissue level
and analyzed the histological signatures of the tumor formation.
Post-mortem BLI analyses of explanted SPL and LI showed high
levels of bioluminescence signals in ICI-treated mice (Figures 2A,
B). Histopathological analyses confirmed numerous EBV+
lymphoid neoplastic lesions with a blast-like phenotype and a
CD20+ and partially CD30+ immunophenotype of different size
and cellular composition. The lesions ranged from relatively small,
diffusely infiltrating or sheet-like tumor formations, often observed
in perivascular localization (Figures 2C–F, left panels, arrows),
to confluent lesions and massive compact tumor masses
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FIGURE 1 | Humanized mice infected with EBV/fLuc and treated with pembrolizumab show high mortality associated with increased EBV spread and tumor development. (A)
Scheme of the experiments. 2 × 105 human CD34+ cord blood (CB) purified hematopoietic stem cells (HSCs) were used for hematopoietic stem cell transplantation (HCT) of sub-
lethally irradiated NRGmice. Fifteen to 17 weeks after HCT, the long-term human immune reconstitution in blood (huCD45+) was confirmed. At this point, mice were infected i.v.,
with the preferentially latent EBV B95-8/fLuc strain (105GRU) or with the lytic EBV M81/fLuc strain (106GRU). Two independent experiments using HSCs from two different CB
donors were performed for each EBVmodel. At 2 weeks post-infections (wpi), bioluminescence imaging (BLI) analyses were performed to determine the baseline of EBV infection
level and to randomize the mice among three cohorts: (i) injected i.p. with phosphate-buffered saline (PBS, corresponding to the control group, CTR), (ii) injected i.p. a low dose
(LD: First administration 3.33 mg/kg at 2 wpi; 1.7 mg/kg every other week applied six times), or with (iii) a high dose (HD: First administration 10 mg/kg at 2 wpi; 5 mg/kg every
other week applied six times). Mice were monitored for disease severity every 2–3 days and body weights were measured weekly. Scores of disease severity or loss of 20% of
body weight were used as termination criteria. Optical imaging analyses and analyses of human immune reconstitution in peripheral blood collections were performed
longitudinally (2, 4, 6, 8 wpi). The experimental endpoint was eight weeks post-infections. The following data was acquired for terminal analyses: % survival, occurrence of weight
loss, occurrence of tumors, EBV load, histopathology, characterization of T cells in blood and tissues, human cytokine profile in plasma. (B, C) Survival curves for humanized mice
infected with the B95-8/fLuc strain (B) or with the M81/fLuc strain (C). A log-rank test (Mantel-Cox) was applied to evaluate the differences in survival. Cohorts: CTR (gray line), LD
(blue line); HD (red line). (D, E)Measurements of body weight relative to the baseline weights on the day of EBV infection. Mice infected with B95-8/fLuc strain (D) or M81/fLuc
strain (E). Cohorts: CTR (grea line), LD (blue line); HD (red line). (F, G) Numbers of macroscopically detectable tumors in mice infected with B95-8/fLuc (F) or with M81/fLuc (G).
Cohorts: CTR (gray dots), LD (blue dots); HD (red dots). (H, I) BLI pictures generated sequentially from week 2 to 8 after EBV infection performed in duplicate experiments for each
EBVmodel and treatment. Pictures were taken of left body side of mice infected with B95-8/fLuc (H) or with M81/fLuc (I). Bioluminescence signal intensities (photons/sec) are
depicted by the color bars on the right side. Black boxes depict dead mice. (J–L)Quantification of EBV spread by BLI for the B95-8/fLuc (J) or M81/fLuc (L) strain. Total Flux
corresponds to the radiance (photons/sec) in each pixel summed over the regions of interest (ROI) area containing the whole left side of the body. The dots represent
quantifications at 2, 4, 6, 8 wpi for each mouse in CTR (open circles) or in pembrolizumab treatment cohorts (filled triangles, LD and HD were combined). (K–M)Quantification of
EBV spread by RT-qPCR. EBV copies per µg DNA were quantified in spleen (SPL) and bone marrow (BM) of mice infected with B95-8/fLuc (K) or with M81/fLuc (M). The dots
represent quantifications for each mouse in CTR (open circles, PBS and KIOVIG controls combined) or in pembrolizumab treatment cohort (filled triangles, LD and HD were
combined). Results of measurements were log-transformed and statistical analyses were performed using unpaired t test with Welch’s correction. Standard deviation is indicated.
Statistical significances are indicated with *P < 0.05, ****P < 0.0001.
TABLE 2 | Summary of EBV spread (by BLI and PCR) and immunologic effects (by FACS, cytokine measurement of plasma and histopathology analyses by multiplex




Analyses N = Mean ST
Dev




BLI p/s* 8 3 7.35 0.17 11 9.32 0.68 <0.0001
PCR BM copy/µg
DNA*
8 3 3.87 0.67 8 4.87 0.36 0.1110
CD4-PD1 MFI PBL* 8 3 4.38 0.14 11 3.36 0.24 0.0001
CD4-PD1 MFI SPL* 8 3 4.94 0.24 11 3.50 0.29 0.0013
% Treg inCD4. SPL 8 3 2.80 1.80 11 6.50 5.70 0.0876
IL-17A pg/ml 8 3 1.63 0.93 10 8.87 9.81 0.0490
IL-10 pg/ml 8 3 416.73 681.52 10 825.43 718.53 0.2867
IL-33 pg/ml 8 3 3.90 0.48 10 10.57 17.06 0.1608
IFN-a pg/ml 8 3 3.07 3.15 10 11.39 12.09 0.0769
IL-12 pg/ml 8 3 10.29 16.37 10 3.56 2.79 0.5734
IL-1b pg/ml 8 3 1.89 0.52 10 2.89 2.59 0.8357
Treg near CD4 LI 8 3 0.02 0.023 11 0.35 0.40 0.0193




Analyses N = Mean ST
Dev
N = Mean ST Dev P
values
BLI p/s* 8 6 9.84 0.68 4 11.65 1.82 0.1387
PCR BM copy/µg
DNA*
5, 7, 8 6 2.83 0.41 8 4.00 1.18 0.0283
CD4-PD1 MFI PBL* 7, 8 6 4.84 0.08 5 3.96 0.41 0.0074
CD4-PD1 MFI SPL* 7, 8 6 5.15 0.06 5 3.99 0.59 0.0112
% Treg in CD4, SPL 7, 8 6 2.80 0.60 5 5.70 7.60 0.0407
IL-17A pg/ml 7, 8 6 3.71 1.73 5 4.07 4.04 0.6623
IL-10 pg/ml 7, 8 6 18.23 10.03 5 9189.12 11248.73 0.0173
IL-33 pg/ml 7, 8 6 3.35 1.03 5 51.80 70.27 0.0087
IFN-a pg/ml 7, 8 6 0.97 0.20 5 25.13 22.94 0.0043
IL-12 pg/ml 7, 8 6 1.51 0.51 5 59.21 105.47 0.0043
IL-1b pg/ml 7, 8 6 1.72 0.46 5 3.84 2.12 0.0498
(A) B95-8 infection. (B) M81 infection. The statistical methods used for analyses are shown in the Supplementary Tables. Significant differences between control and pembrolizumab-
treated mice are shown in bold and italics. The original values for PD-1 MFI (*) were log-transformed before statistical tests. The reduced detections of PD-1 on CD4+ T cells were highly
significant for both models (p values are underlined). The frequencies of CD4+ Tregs in spleens were increased for both models. The proximity of Tregs to T cells of liver for the B95-8 model
was analyzed by multiplex immunohistochemistry analyses. The cytokine responses were variable for the two models.
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(Figures 2C–F, right panels, see areas marked with asterisks). In LI,
large coherent tumor formations were almost exclusively observed
in pembrolizumab treatment groups, while in control animals
tumors tended to be smaller and only rarely confluent. In
ICI-treated mice, large, partially necrotic tumor masses in SPL
(Figures 2C–E, left panel) and LI (Figures 2C–E, right panels) were
consistently present. The neoplastic partially CD30+ and CD20+
cells were associated with a dense CD3+ T-lymphocytic infiltrate
(Figures 2E, F). Immune subtyping revealed that this T cell
infiltrate was mainly composed of CD8+ cytotoxic T lymphocytes
(CTLs) and CD4+ T helper cells (Th) (Figures 2G, H). Brisk T cell
infiltrates were predominantly observed in small, presumably early-
stage perivascular lesions (Figures 2C–H, arrows), where fewer
neoplastic cells expressing EBER were present in relation to the
overall amount of cells, and at the margins of coherent tumor









FIGURE 2 | Analyses of explanted spleen and liver showed increased EBV/fLuc spread, inflammation, and neoplasia after pembrolizumab treatment.
(A, B) Bioluminescence imaging analyses performed with explanted spleen and liver from representative B95-8/fLuc (A) or from representative M81/fLuc-infected
mice (B). Tissues from representative non-treated control (CTR) mice are shown. Bioluminescence signal intensities (photons/sec) are depicted by the color bars on
the right side. (C–J) Histopathological analyses of spleen (C–I) and liver (D–J) of representative mice infected with EBV/B95-8/fLuc and non-treated (CTR, left side)
or treated with pembrolizumab (Pembro, right side). (C, D) Giemsa, EBER: In both organs, the perivascular spread of EBV/B95-8/fLuc infected neoplastic cells is
observed. More disseminated infection and larger tumors were observed in pembrolizumab-treated than in control mice. Stars indicate perivascular angiocentric
neoplastic growth. (E, F) CD30, CD20/CD3 duplex: The CD30- and CD20-expressing tumors and perivascular infiltrates resemble human B-cell neoplasia,
corresponding to diffuse large B-cell lymphoma, and are surrounded or invaded by variable amounts of tumor-infiltrating CD3+ lymphocytes (TILs). (G, H) CD8, CD4:
Early perivascular lesions display a largely balanced CD4/CD8 ratio. In the center of tumor bulk mass, the balance is shifted towards CD8+ cytotoxic T lymphocytes
(CTLs). (I, J) Ki67, PD-L1: proliferating cells observed at a higher density in tumor areas, which also correlates with PD-L1 expression. Digital whole slides scanned
at 40×; black bars correspond to 600 µm (full image) and 100 µm (inserts).
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2C–H, see areas marked with asterisks) showed relatively fewer T
cells, particularly fewer CD4+ Th cells, if compared to tumor
margins and smaller perivascular tumor cell groups (Figures 2G,
H). The tumor areas corresponded to proliferative activity: Ki67+
cells with morphological features indicative of neoplastic
lymphoproliferation were more prominent in tissues of ICI-
treated mice and tumor formations were associated with higher
expression of PD-L1 (Figures 2I, J). Altogether, these descriptive
analyses indicated that infiltrating T lymphocytes were more
pronounced, and potentially more active, in early stages of tumor
invasion and at the invasive edges, but less prominent in the center
of the large tumor masses observed in ICI-treated mice, a pattern
resembling “immune excluded” tumors (36).
PD-1 Blockade Promotes Epstein–Barr
Virus Spread into the Central Nervous
System
Brains explanted of ICI-treated mice showed detectable BLI
signals, but this was not the case for brains of control mice
(Figures 3A, B). Histopathology confirmed presence of EBER+
cells in brains of infected mice. In two cases of the ICI-treated







FIGURE 3 | Pembrolizumab treatment is associated with spread of EBV/fLuc to the central nervous system. (A, B) Bioluminescence images showing representative EBV
signal patterns in brains from mice infected with B95-8/fLuc (A) or with M81/fLuc (B) and treated with pembrolizumab (Pembro; most severely affected animals shown in each
group), compared with non-treated controls (CTR). The bioluminescence signal intensities (photons/sec) are depicted by the color bar on the right side. (C, D) In-situ
hybridization for detection of Epstein-Barr encoded RNA (EBER)-1 in brains of mice infected with B95-8/fLuc and treated with pembrolizumab. Observed patterns include
invasion of tumor cells into the plexus choroideus (white inserts), as well as into periventricular brain parenchyma (red insert) and meningeal tumor spread (blue inserts). The
green arrows indicate single tumor cells associated with blood vessels. (E) Comparison with three representative examples of human EBV-positive monomorphic
transplantation-associated B-PTLD, with clinical manifestation as primary CNS lymphoma (PCNSL) revealed similar patterns of intraparenchymal (Case 01), perivascular (Case
02), and massive angiocentric/diffuse growth with meningeal spread (Case 03). (F) Control animals did not show any involvement of the plexus choroideus or periventricular
brain areas. Only single EBER-positive cells in intravascular localization were detected (green arrows). (G–J) The immunophenotype of the neoplastic cells invading the brain of
ICI-treated mice corresponded to the phenotype of the peripheral neoplastic population with variable CD30+, and constant CD20+ expression. The majority of neoplastic cells
expressed EBNA2 but not LMP1 and were actively proliferating (CD20+/Ki67+). (G–H) and (I–J) Analyses of duplicate mice infected with B95-8/fLuc and M81/fLuc and
treated with pembrolizumab, respectively. (K) Multiplexed image of two mouse brains from B95-8/fLuc infection model after pembrolizumab treatment confirmed
co-localization of neoplastic cells (CD20+, white; CD30+, magenta) and T lymphocytes (CD8+ yellow; CD4+, green). Lymphocytes were actively proliferating (Ki67+, red),
particularly CD8 (blue arrows). DAPI (blue) is used to mark cell nucleus. Bars correspond to 200 µm (full image) and 50 µm (inserts).
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local CNSmanifestations of EBER+ LPD were observed with blast-
like morphological appearance (Figures 3C, D): (i) Intra- or
perivascular spread: single tumor cells were found within the
lumen of small, mostly capillary blood vessels (Figure 3C, blue
and white inserts, brown arrows) and close to the vessel walls in
small veins (Figure 3D, blue inserts, brown arrows), resembling
patterns observed in brain manifestations of human PTLD
(Figure 3E, Case 01 and 02); (ii) Meningeal spread: coherent
sheets of tumor cells forming a meningeal infiltration at the brain
surface (Figures 3C, D) and resembling neoplastic meningitis in
corresponding human diseases, e.g., EBV+ PTLD (Figure 3E, Case
03); (iii) Diffuse brain infiltration: diffusely infiltrating tumor cells
formed a partially perivascular tumor mass, mixed with pre-
existing brain tissue (Figure 3C, red insert), corresponding to
the characteristic patterns of human (primary) CNS lymphoma
and/or monomorphic PTLD (Figure 3E, Case 01 and 03). In
addition to these patterns, there was also diffuse involvement of
the choroid plexus in treated mice. In contrast, the control animals
showed only occasionally single EBER+ cells associated with blood
vessels but nomeningeal or intraparenchymal involvement and no
positive cells in the choroid plexus (Figure 3F). The
morphological phenotype of the EBER+ tumor cells
corresponded to the extracerebral manifestations (Figures 3G–J,
top panels), as well as the immune phenotype with inconsistent
CD30 expression, CD20 positivity, and high Ki67+ proliferative
activity (Figures 3G–J, middle panels). EBNA2 and LMP1
staining indicated latently-infected EBV+ cell population
(Figures 3G–J lower panels). In-depth analysis of the tumor
spread to the CNS by multiplex-immunohistochemistry
confirmed the B cell lineage of the blast-like tumor cells, the
high proliferative activity, the partial expression of CD30, and a
scarce bystanding infiltration with some CD4+ and CD8+
lymphocytes, the latter frequently co-expressing the proliferation
marker Ki67 (Figure 3K).
PD-1 Blockade Results in Lower
Frequencies of Circulating Cytotoxic T
Lymphocytes and Th Cells and Reduced
Detection of PD-1 on T Cells
Longitudinal analyses of blood samples were performed to
monitor the frequencies of circulating human T cells (see
Figure S1A for the flow cytometry gating strategy). The
frequencies of huCD45+ hematopoietic cells at the time of EBV
infections were comparable for both models (B95-8/fLuc: mean
26.4%; M81/fLuc: mean 33.7%). Relative to controls, the
frequency of blood huCD45+ cells was significantly reduced for
mice infected with M81/fLuc and treated with ICI (M81 model
7–8 wpi: CTR vs Pembro, P = 0.0017; Figures S2A, B; see Tables
S4, 5 for descriptive data). Consistent with our previous
observations after EBV/B95-8 infection (24), significant
increase in CD3+ frequencies in blood (Figures 4A, B, Tables
S4, 5) and significant decrease in frequencies of CD19+ B cells
were observed from 4 to 8 wpi (Figures S2C, D, Tables S4, 5).
ICI treated mice at 6–8 wpi, however, showed lower frequencies
of CD3+, CD8+, and CD4+ T cells compared with controls
(Figures 4A–D, G, H; Tables S4, 5). We have observed that T
cells pre-treated with pembrolizumab for 30 min in vitro, washed
and then stained with the fluorochrome-labeled monoclonal
anti-PD-1 antibody (clone EH12.2H7) showed a drastic
reduction on the detectable PD-1 (Figure S2E). The most
l ikely explanation is that the epitope is bound by
pembrolizumab and this blocks the antibody used for immune
staining of T cells, resulting in epitope “masking.” This
“masking” effect was confirmed by measurement of the mean
fluorescence intensity (MFI) of PD-1 analyses of T cells from 3 to
4 wpi, i.e. 2 weeks after initiation of therapy (Figures 4E, F, I, J;
Figure S1A; Table 2, Tables S4, 5). For both models, this PD-1
masking effect was consistently more pronounced for CD4+
(CTR vs Pembro, P < 0.01 to P < 0.0001) compared to CD8+
T cells.
PD-1 Blockade Results in Increased
Levels of Several Human Cytokines in
Plasma of Epstein–Barr Virus Infected
Mice
Plasma was collected at the endpoint for analyses of human
cytokines in the circulation. The levels of both pro-inflammatory
(IL-6, IL-8, IFN-a, IFN-g, MCP-1, and TNF-a) and immune-
suppressive (IL-10) cytokines were elevated in ICI-treated mice
(Figures 4K, L, Figures S2F, G, Table 2, Table S6). Treatment of
EBV-M81/fLuc-infected mice with KIOVIG did not affect the
immune reconstitution profile nor cytokine levels and, therefore,
these immune-modulations were only seen in mice after EBV
infection and PD-1 blockade (Figures S2H–J). Administration
of pembrolizumab alone, in absence of EBV did not have a
comparable effect with either treated or untreated groups
(Figures S2H–J).
Biomarkers Identified in Blood and Plasma
After Immune Checkpoint Inhibition
Treatment
The datasets of both EBV-models were merged for the
identification of concordant biomarkers defining a response to
pembrolizumab treatment (Figure 4M). Overall, in comparison
with control mice, ICI-treated mice showed significant: (i) lower
frequencies of CD3+/CD45+ and CD4+/CD45+ T cells, (ii) lower
MFI of PD-1 detectable on CD4+ cells; (iii) elevated levels of IL-
10 and IFN-a. In summary, PD-1 blockade applied during an
active EBV infection resulted in lower detection of PD-1high
circulating lymphocytes (particularly for CD4+ T cells) and in a
profound modulation of the cytokine levels in plasma.
PD-1 Blockade Promotes a Quantitative
Loss of CD4+ T Cells in Lymphatic Tissues
The immune composition of total human T cell counts in
lymphatic tissues (SPL, LN, BM, and Thy) was performed to
characterize the immunologic effects of ICI on CD8+ and CD4+
T cells in further detail (Figure 5, see Tables S7, 8 for
descriptive data). For the B95-8/fLuc model, ICI treatment
promoted a modest expansion of the CD8+ T cell
compartment in lymphatic tissues (Figure 5A), whereas for the
M81/fLuc model a significant reduction was seen (Figure 5B,
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FIGURE 4 | Reduced frequencies of human T lymphocytes in peripheral blood and increased concentrations of human cytokines in plasma after PD-1 blockade during
active EBV infections. Peripheral blood was collected on the day prior to EBV infection (time-point 0) and 2 weeks post-infections (wpi), as baseline values for randomization
(shaded graphs). Non-treated control mice (CTR, open circles) and pembrolizumab treated cohorts are shown (filled triangles; low-dose and high-dose treatments were
merged for the analyses, each dot represents a mouse analyzed at the corresponding time point). After initiation of pembrolizumab treatment, peripheral blood was collected at
3–4, 5–6, and 8 wpi. The different EBV infection models (B95-8/fLuc; left panels and M81/fLuc; right panels) were analyzed separately regarding lymphocytes and cytokines
and then the data was merged for power analyses and identification of markers associated with response. (A–J) Flow cytometry analyses of peripheral blood lymphocytes.
(A, B) Frequencies (%) of human CD45+/CD3+ lymphocytes were reduced after pembrolizumab treatment. (C, D) Frequencies (%) of human CD45+/CD8+ lymphocytes were
reduced after pembrolizumab treatment. (E, F) Mean fluorescence intensities (MFI) of PD-1 detected on the surface of CD8+ T cells were reduced after pembrolizumab
treatment. (G, H) Frequencies (%) of human CD45+/CD4+ lymphocytes were reduced after pembrolizumab treatment. (I, J) MFI of PD-1 detected on the surface of CD4+
T cells were significantly reduced after pembrolizumab treatment. Statistical analyses for flow cytometry data was performed using unpaired t test with Welch’s correction.
Standard deviation is indicated. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. (K, L) Concentration human cytokines (pg/ml) at 8 wpi showing elevation for several
cytokines in plasma of mice infected B95-8/fLuc (K) or M81/fLuc (L) treated with pembrolizumab. Mann-Whitney t test was used to compare the control and treatment
groups. Standard deviation is indicated. *P < 0.05, **P < 0.01. # indicates parameters with some values being beyond the lower limit of detection (LOD), LOD was used for
these samples to analyze the differences. (M) Global analysis for power analyses and identification of T cell and cytokine patterns at 8 wpi. The datasets from the B95-8/fLuc
and M81/fLuc infection models were merged. Kolmogorov-Smirnov-Test (KS test; D > 0.3, P < 0.05) is depicted for flow cytometry and cytokine datasets showing markers
with significant difference between control (CTR, red) and pembrolizumab treatment (Pembro, blue). P-values determined for each biomarker are indicated below the box plots.
The top biomarkers associated with pembrolizumab treatment were: Reduced %CD3/CD45 (P = 0.0003), reduced %CD4/CD45 (P = 0.0182), reduced MFI of PD-1
expression on CD4+ cells (P = 0.0001), increased IL-10 (P = 0.0086) and IFN-a (P = 0.0090) levels in plasma.
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FIGURE 5 | The absolute numbers of human T lymphocytes in lymphatic tissues increased for the B95-8/fLuc model and decreased for the M81/fLuc model after
PD-1 blockade. The absolute numbers of viable lymphocytes recovered from spleen (SPL), lymph nodes (LN), bone marrow (BM), and thymus (Thy) were counted
and, after flow cytometry analyses, the absolute numbers of each lineage was calculated. Non-treated control mice (CTR, open circles) and pembrolizumab-treated
cohorts are shown (filled triangles; low-dose and high-dose treatments were merged for the analyses; each dot represents a mouse analyzed at the terminal time
point). Only mice surviving until the terminal analyses at 8 wpi were included in the terminal flow cytometry analyses. (A, B, E, F). Quantified total lymphocyte
numbers (# cells) calculated for CD8+ T cells (A, B) and CD4+ T cells (E, F) for each organ. Note the increased numbers of lymphocytes for the B95-8/fLuc models
and the decreased numbers for the M81/fLuc models for the pembrolizumab-treated mice. (C, D, G, H) Mean fluorescence intensity (MFI) for PD-1 detection for
CD8+ T cells (C, D) and CD4+ T cells (G, H) showing overall significantly reduced PD-1 detection after pembrolizumab treatment for both models. Unpaired t test
with Welch’s correction was used to compare treatment groups. *P < 0.05, **P < 0.01, ****P < 0.0001. Standard deviation is indicated. (I) Global power analyses
and biomarker identification. The flow cytometry datasets of spleen of B95-8/fLuc and M81/fLuc models were merged. Kolmogorov-Smirnov Test (KS test; D > 0.65,
P < 0.05) is depicted. The biomarkers identified with significant differences between control (CTR, open circles) and pembrolizumab treatment (Pembro, filled
triangles) were: Lower SPL % CD4/CD45 (P = 0.0008); lower BM #CD4/CD45 (P = 0.0319); lower MFI for PD-1 in CD4+ cells (P < 0.0001); lower MFI for PD-1 in
CD8+ cells (P = 0.0003). P-values determined for each marker are indicated below the graphs.
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P < 0.05). The CD8+ T cells from ICI-treated mice were PD-1Low,
recapitulating the epitope masking effect (Figures 5C, D).
Numbers of CD4+ T cells were reduced compared to control in
BM of ICI-treated mice for both EBV models (P < 0.05), as well
as in the SPL of M81 model (P < 0.01) (Figures 5E, F). For the
mice surviving until the endpoint analyses, PD-1 masking of
CD4+ T cells was more pronounced in lymphatic tissues of mice
infected with B95-8 than infected with M81 (P < 0.05 to P <
0.0001, Figures 5G, H; Tables S7, 8). Overall, the MFIs
measured for PD-1 in CD4+ T cells were significantly reduced
in ICI-treated mice compared to controls, although this varied
for different tissues (P < 0.05 to P < 0.0001, Figures 5G, H;
Tables S7, 8).
Biomarkers Identified in Lymphatic
Tissues After Immune Checkpoint
Inhibition Treatment
The datasets of tissue analyses of both EBV-models were merged
for identification of biomarkers of response to pembrolizumab,
showing: (i) lower frequencies and lower absolute numbers of
CD4+/CD45+ in SPL (P = 0.0008) and BM (P = 0.0319) and (ii)
lower MFI of PD-1 detection on CD4+ cells (P < 0.0001) and
CD8+ T cells (P = 0.0003) (Figure 5I). In summary,
pembrolizumab treatment after EBV infection consistently
lowered the numbers of PD-1+CD4+ T cells in lymphatic tissues.
PD-1 Blockade Promotes T Cell
Exhaustion and High Frequencies
of Regulatory T Cells in Spleen
Splenocytes were analyzed to identify markers of immune
exhaustion. TIM-3 analyses were included because TIM-3
cooperates with PD-1 in T cell dysfunction in chronic viral
infections and PD-1+/TIM-3+ CD8+ T cells express high levels of
IL-10 (37). For both CD8+ and CD4+ T cell sub-populations,
treated mice showed higher frequencies of TIM-3+ cells (Figures
6A–D; Tables S7, 8; see the gating strategy in Figure S1B).
Higher frequencies of cells expressing TIM-3 were observed for
PD-1high cells, indicating that T cells evading or not masked with
pembrolizumab were more exhausted. In another panel, LAG-3
was analyzed in conjunction with the activation marker CD69
(Figures 6E–H; Tables S7, 8, see gating strategy in Figure S1C).
LAG-3 is another checkpoint receptor that defines a potent
regulatory T cell subset that occurs more frequently in cancer
patients and is expanded at tumor sites (38). The frequencies of
CD8+ and CD4+ T cells positive for both CD69 and LAG-3 were
moderately increased for treated mice infected with B95-8/fLuc,
while significantly increased for M81/fLuc infected and ICI-
treated mice (Figures 6E–H). Altogether, these results
indicated that the PD-1 blockade after EBV infection
magnified T cell exhaustion. As complementary analyses, the
presence of CD25+/FoxP3+/CD4+ regulatory T cells (Tregs) in
spleen was determined. A modest increase of Tregs proportion in
CD4 cells was observed for the B95-8/fLuc-infected treated mice
relative to controls (Figures 6I, J, Tables S7), while the Tregs
were significantly amplified in mice infected with M81/fLuc after
ICI treatment (Figures 6K, L, Table S8, for gating strategy see
Figure S1D). Therefore, both exhaustion of CD4+ and CD8+ T
cells and higher frequencies of Tregs were promoted by PD-1
blockade after EBV-infection, and this signature was even more
noticeable for the M81/fLuc lytic model.
PD-1 Blockade Is Associated With
Increased Densities of CD4+/FoxP3+
T Cells Within Tumors
The tumor immune microenvironment was assessed using a
multiplexed immunohistochemistry approach. The cell densities
and distance metrics within the tumor or parenchyma areas
using tissues obtained from B95-8/fLuc-infected mice were
analyzed (Figures 7A–C, representative example of immune
cell phenotyping in a liver tumor and adjacent parenchyma by
co-staining for DAPI, CD20, CD8, CD4, the proliferation marker
Ki67, and the Treg marker FoxP3; for corresponding analyses in
spleen tissue see Figure S3A). The density of proliferating CD4+
T cells showed an overall modest reduction for ICI-treated mice
compared with controls, however, this did not occur for CD8+ T
cells (Figures 7D, E, liver; Figures S3C, D, spleen; Table S9).
Further, higher densities of CD4+/FoxP3+ T cells, were observed
within the tumor area (Figure 7F, liver; Figure S3E, spleen).
CD8+/FoxP3+ T cells, another subset of immunosuppressive cells,
were also present in liver parenchyma of ICI-treated, but not in the
control group (Figure 7G, liver; Figure S3F, spleen). The analysis
of distance metrics between different T cell subtypes in liver tissues
(Figure 7C, liver; for spleen see Figure S3B) showed that the
average presence of CD4+/FoxP3+ Tregs in up to 200 µm radius
around any single FoxP3- T cell (both CD4+/FoxP3− or CD8+/
FoxP3−) was higher in the pembrolizumab-treated group than in
controls (P < 0.05, Figures 7H, I, liver; Table 2, Table S9),
suggesting that immune regulatory T cells with CD4+/FoxP3+ and
CD8+/FoxP3+ phenotypes were enriched. This was observed in the
immediate microenvironment of T-effector and helper cells of ICI-
treated mice with more advanced tumors indicating a higher
chance of direct cell-to-cell interactions, potentially associated
with immune suppression and aggravation of EBV spread upon
PD-1 blockade.
DISCUSSION
Several human malignancies are initiated by viral oncogenesis,
such as EBV, human papillomavirus (HPV), hepatitis B virus
(HBV), and hepatitis C virus (HCV). Currently, there are several
ongoing clinical trials of ICIs to combat virus-associated cancers
(39). For example, pembrolizumab is currently being tested for
the treatment of EBV+ nasopharyngeal carcinoma (NPC), EBV+
Non-Hodgkin’s disease, EBV+ NK/T cell lymphoma, EBV+
gastric cancer, HPV+ cervical cancer, and HPV+ head and neck
squamous cell carcinoma (39). One potential risk to be evaluated
is that viral immune evasion mechanisms may develop to
counteract the human immune responses affecting the mode of
action of ICI. On the other hand, a substantial amount of cancer
patients treated with ICI occasionally show HPD, but the
etiological reasons (such as for example action of underlying
infections) are not yet fully understood (40–42). To avoid HPD
or to mitigate its risks, the causes and early predictors associated
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with this phenomenon require investigation. The tumor burden,
level of immune infiltration in the tumor, quality of immune
responses, immune biomarkers, and existence immunomodulatory
PD-1 positive lymphocytes have all been associated with HPD
(43–47). Wong et al. reported a case series of four patients with
advanced hepatocellular carcinoma with chronic HBV infections
treated with ICIs and demonstrating rapid radiological progression
and HPD (48). A recent review summarizing the results on the
safety and efficacy of ICI in HBV/HCV-infected advanced cancer
patients concluded that it was safe and effective, but warned about
the reactivation of hepatitis virus in some cases (49). Currently,
there is no clear relationship embracing ICI, cancer, chronic
infections, irAEs, and HPD. Recently, it was shown in a mouse









FIGURE 6 | The frequencies of T cells expressing TIM-3 or LAG-3 exhaustion markers or a regulatory T cell immunophenotype increased after pembrolizumab
treatment. Frequencies of marker-positive lymphocytes recovered from spleen (SPL) comparing non-treated control mice (CTR, open circles) and pembrolizumab-treated
cohorts are shown (filled triangles; low-dose and high-dose treatments were merged for the analyses). Only mice surviving until the terminal analyses at 8 wpi were
included in the terminal flow cytometry analyses. (A–D) Frequencies (%) of TIM-3+ in CD45+/CD8+ (A, B) and of TIM-3+ in CD45+/CD4+ (C, D) T cells are shown. PD-1+
(left side) or PD-1− (right side) CD8 or CD4 subpopulations were analyzed separately. Higher proportion of TIM-3+ cells was observed more clearly for PD1+ T cells for
both models. (E–H) Frequencies (%) of LAG-3+ in CD45+/CD8+ (E, F) and LAG-3+ in CD45+/CD4+ (G, H) T cells are shown. CD69+ (left side) or CD69- (right side) CD8
or CD4 subpopulations were analyzed separately. Significantly higher proportion of LAG-3+ T cells were observed for activated CD69+ T cells for mice infected with M81/
EBV/fLuc and treated with pembrolizumab. (I–L) Frequencies (%) of CD25+/FoxP3+/CD45+ regulatory (I, K) and CD45RA-/CD25+/FoxP3+/CD45+ activated regulatory T
cells (J, L) detected within the human CD4+ cells for B95-8 (I, J) and M81 model (K, L). Pembrolizumab treatment was associated with higher proportion of regulatory T
cells for both models. Unpaired Welch’s t test was used to compare treatment groups. *P < 0.05. Standard deviation is indicated.
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mounted rampant CD4+ T helper type 1 (Th1) responses driving
lethal disseminated tuberculosis (50). In another alarming report,
metastatic melanoma patient suffered fatal encephalitis after PD-1
blockade therapy with pembrolizumab. The affected brain tissue
contained lymphocytes infected with EBV with a concurrent
infiltration of memory cytotoxic CD4+ and CD8+ T cells reactive
against EBV (51). Therefore, as these clinical case reports are
summing up, there is a significant need to examine pre-clinically









FIGURE 7 | Lower overall infiltration of CD4+ T cells but higher density and chance of intercellular interactions of regulatory T cells in tumors of mice infected with
EBV/B95-8/fLuc and treated with pembrolizumab. (A) Representative example of a multiplexed immunohistochemical (mIHC) staining of liver tissue of a B95-8/fLuc-
infected and pembrolizumab-treated humanized mouse followed by multispectral image (MSI) analysis/color deconvolution into six channels representing CD20+
(white), Ki67+ (magenta), CD4+ (green), CD8+ (yellow), FoxP3+ (red), and DAPI (blue) markers. (B) Tissue segmentation between the perivascular tumor mass (red)
and the non-neoplastic parenchyma (green). Expectedly, the tumor area corresponds with high density of proliferating CD20+ blast-like cells (A, B). (C) Comprehensive
distance mapping between FoxP3+ (red dots) and FoxP3- T-cells (cyan dots). (D) The tumor areas of treated animals (black triangles, n = 11) showed fewer CD4+ T cells
than controls (open circles, n = 3). (E) The parenchyma area is characterized by a prominent population of proliferating CD8+ cells, with a trend towards higher densities in
treated animals (not significant). (F) Densities of proliferating Ki67+CD4+ Treg cells in the parenchyma or in the tumor tissue, with an increase of tumor-infiltrating
FoxP3+/CD4+ Treg cells in the pembrolizumab-treated group (not significant), (G) that was also observed for parenchyma FoxP3+/CD8+ Treg cells (not significant). (H)
Distance metrics between FoxP3+/CD4+ Tregs or (I) FoxP3+/CD8+ Tregs revealing significantly increased average number of FoxP3+/CD4+ within a radius of 200 µm around
any single CD4+ or CD8+ T cells residing in the tumor area for pembrolizumab-treated (black triangles) mice compared with control (open circles) mice. Unpaired t test with
Welch’s correction was applied to calculate statistical significance. Standard deviation is indicated. *P < 0.05.
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There were previously two discordant reports in the literature
concerning the effects of PD-1 blockade tested pre-clinically in
mouse models for the treatment of EBV-related PTLD and
DLBCL (Table 1). Corroborating our results, Münz and
colleagues showed that fully humanized mice infected with the
B95-8 strain and treated with a PD-1 blocking mAb developed
rampant EBV spread and inflammatory reactions (25) (Table 1).
Here, we showed that these results could be reproduced with
pembrolizumab and for both the B95-8 (preferentially latent)
andM81 (preferentially lytic) EBV infectionmodels. Therefore, we
suggest that PD-1 blocking in the setting of a primary infection and
T cell priming can lead to uncontrolled and widespread EBV
infections and development of neoplasias (PTLD and DLBCL-like
tumors). Incidentally, pembrolizumab treatment affected
even more drastically mice infected with M81, resulting in
significantly accelerated and increased death rates. One aspect
that has to be acknowledged in respect to the fully humanized
mouse models of EBV infection presented by Chatterjee et al. (25)
and by this current work is that their immune reconstitution at the
time of infection was biased towards a high abundance of B cells
(>50%) relative to T cells (<30%). These high levels of B cells, which
are not seen inhumans after transplantation,may have predisposed
a more aggressive PTLD development in the mice. Taking this bias
in consideration, we may be overestimating the substantial
detrimental immunomodulatory effects caused by pembrolizumab.
Of note, there is a clear discrepancy between our results and
those of Kenney and collaborators who observed lower tumor
burden after PD-1 blockade when using the M81 viral strain in a
not fully humanized model (27) (Table 1). The most
straightforward explanation for the different results is that they
pre-treated the mature B and T cell mixture in vitro with the PD-
1 and CTLA-4 blocking mAbs and then administered the cells
into the mice. Therefore, this ex vivo pre-treatment per se may
have stimulated the adoptively transferred human T cells to
become more xeno-reactive in the mice and to expand more
strongly than the co-administered infected B cells. The activated
and expanded T cells could eventually kill or inhibit the
outgrowth of EBV-infected malignant B cells in vivo. This
xenograft model was carried on only for 4 weeks, as the
adoptively transferred human T cells can strongly react against
mouse tissues and eventually result into lethal xeno-GvHD. This
adoptive transfer mouse model strongly deviates from PTLD in
humans, since after HCT the adoptively transferred T cells from
the donor are at least partially matched through the major
histocompatibility complexes (MHCs) to the recipient and
there is also donor-derived thymopoiesis.
On the other hand, in fully humanized mouse models
reported by Chatterjee and by this current work, the human T
cells undergo an endogenous development (18, 25). The
hematopoietic progenitors home in the bone marrow, travel
through the thymus for positive and negative selection of
functional non self-reactive T cell receptors (TCRs). TCR
restriction is mediated by the MHC of the mouse and of the
HSC donor. The developed human TCR+/CD4+ T cells and in
lower frequencies TCR+/CD8+ T cells, eventually home in the
lymphatic tissues and organs. Upon vaccination of fully
humanized mice, the naïve human T cells show typical signs of
priming, and change their immunophenotype from naïve to
memory subtypes (29). Functional human B cells binding to
viral antigens also develop in humanized mice with full
maturation after class switch (30). Thus, these HIS models
reflect homeostatic modulations and are multidimensional, as T
cells with diverse functions and at several stages of differentiation
co-exist in different tissues. From the preclinical perspective, it is
indeed more challenging to perform studies in fully humanized
mice, but these complexities reflect intrinsic mechanisms that may
be missed in in vitro or in simpler xenograft models.
Primarily, the main mechanistic prospect of ICI is the release of
inhibited CD8+ memory TILs through the blockade of the PD-1/
PD-L1 axis in order to revert their functionality (3, 43).
Nonetheless, less is reported about the blockade of the PD-1/PD-
L1 axis during the priming and expansion phase of naïve CD8+ T
cells, which occurs in humans and mice with acute infections, such
as lytic EBV infections (24, 25). Indeed, it has previously been
shown that downregulation of PD-1 expression prevented T cell
proliferation by accelerating a T cell early differentiation (52).
The significant amplification of several human cytokines that
we observed in the plasma of M81-infected mice after PD-1
blockade (IL-10, IL-33, IFN-a, IL-12p70, and IL-1b) revealed the
ignition of a profound inflammatory response. The spread of viral
infection systemically and the remarkable infiltration of EBV+
PTLD into the CNS indicated a defaulted TIL response. This
worrisome finding suggested that the aggravated infection and/or
inflammation could potentially weaken the blood-brain-barrier. Of
note, we observed that LAG-3 was strongly upregulated on CD8+
and CD4+ T cells after PD-1 blockade. Therefore, it is possible that
the viral immune escape maneuvered the T cell exhaustion through
upregulation of other suppressive receptors, like LAG-3.
In addition, our data also underscored bystander effects
involving the participation of CD4+PD-1+ T cells. Their
collapse and/or conversion into dysfunctional exhausted cells
or Tregs likely contributed to viral escape and to irAEs. The role
of Tregs seemed to be particularly critical within the tumor
microenvironment on the initial stages of tumor development.
Although we have not yet identified an EBV-specific molecular
and immunologic mechanism by which PD-1 blockade may have
affected the CD4+ Tregs function, some correlations exist with
neoplasias caused by EBV. For example, in vitro studies showed
that EBV latency III–transformed B cells promoted expansion of
autologous FoxP3+ CD39high PD-1+ CTLA-4+ Helios+ GITR+
LAG-3+ CD4 Tregs (53). Another study showed that homing of
Tregs in EBV+ HL tumor microenvironment is significantly
increased around EBV-infected cell nests (54). Tregs also
effectively populate EBV+ gastric carcinoma tumors and
express PD-1 (55). In EBV+ NPC, EBNA-1-and LMP2-specific
CD8+ CTL responses can be suppressed in vitro by Tregs and
their depletion with a recombinant fusion protein (Ontak)
reverted this immune suppression (56). Therefore, Treg
depletion combined with PD-1 blockade could be eventually
tested, with the caveat that persistent CD25 immune depletion
can lead to immune deficiency. Future studies are needed to
clarify the participation of Tregs in EBV+ HPD.
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Remarkably, we also noticed a conspicuous presence of CD8+/
FoxP3+ cells in tumors, endorsing that TILs can be subverted to
immunosuppressive Tregs. Incidentally, CD25+CD8+FoxP3+ Tregs
were previously described as cells showing rapid expansion in blood
and tissues of rhesus macaques during the acute phase of simian
immune deficiency (SIV) infection (57). CD8+ Tregs were also
observed in humans infected with the human immune deficiency
virus and expressed low levels of granzyme B and perforin,
suggesting that they did not possess killing potential but were
related to immune suppressor functions (57). Thus, development
of virus-induced CD8+ Tregs during acute infection may be a
mechanism to curb the primary immune response so that the
pathogen can take hold. Nonetheless, variability of PD-1+ T cell
populations emerging in different infections has been shown,
pointing to diverse mechanisms inducing suppressive T cell types.
For example, for acute influenza A virus infection, mainly central
memory CD8+ T cells with a PD-1+2B4+CXCR5+ phenotype thrive
after viral clearance (58). In contrast, CD8+ T cells with these
characteristics were completely absent in viremic HIV infected
individuals (58).
Concluding, our study endorsed preclinical (25) and clinical
observations (51) regarding the interaction of EBV infection with
PD-1 blockade in sparking EBV spread. One novel mechanistic
insight provided is the possible role of immunosuppressive
PD1+CD4+ Tregs cells. One limitation of our current studies
was that a single agent, pembrolizumab, was tested for ICI and in a
single treatment schedule. It is possible that other ICIs or treatments
at different doses or time points may give different results. For
instance, blocking PD-L1 on the tumor side may produce less
immunosuppressive effects on T cell effects primed against EBV+
PTLD or DLBCL. Additional studies in humanized mice using ICI
drugs in the preclinical testing pipeline can provide predictive
information for very critical decisions that clinicians will
eventually have to make, i.e., to opt for single or combinations of
targets for treatment of EBV+ tumors. From the translational
perspective, as clinical trials against different malignancies
exploring the use of ICI in combination with chemotherapy,
rituximab, or small drugs against EBV+ malignancies are
emerging, it would be recommendable to first evaluate if the
patients have active EBV infections and second to monitor the
patients for possible EBV reactivations. Therefore, these findings
warrant careful preclinical assessment of the EBV status in patients
in order to minimize the side effects and improve the outcomes for
patients treated with PD-1 blockade to avoid irAEs and HPD.
Noteworthy, this report illustrates discordant interpretations of
preclinical results (Table 1), advocating for a transparent
reporting of the methodological approaches used towards the
“Minimal Information for Standardization of Humanized Mice”
(MISHUM) so that the field can further evolve (18).
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